Recombinant Human LY9 protein

中文名： 重组人(LY9)蛋白
别名： LY9;T-lymphocyte surface antigen Ly-9

货号: PA1000-1856

Price： ￥询价

20μg 50μg 100μg ＞100μg

数量：

大包装询价

产品详情

纯度	>95%SDS-PAGE.
种属	Human
靶点	LY9
Uniprot No	Q9HBG7
内毒素	< 0.01EU/μg
表达宿主	E.coli
表达区间	48-454aa
氨基酸序列	KDSAPTVVSGILGGSVTLPLNISVDTEIENVIWIGPKNALAFA RPKENVTIMVKSYLGRLDIT KWSYSLCISN LTLNDAGSYK AQINQRNFEVTTEEEFTLFVYEQLQEPQVTMKSVKVSENFSCNITLMCSV KGAEKSVLYSWTPREPHASESNGGSILTVSRTPCDPDLPYICTAQNPVSQ RSSLPVHVGQFCTDPGASRGGTTGETVVGVLGEPVTLPLALPACRDTEKV VWLFNTSIISKEREEAATADPLIKSRDPYKNRVWVSSQDCSLKISQLKIE DAGPYHAYVCSEASSVTSMTHVTLLIYRRLRKPKITWSLRHSEDGICRIS LTCSVEDGGN TVMYTWTPLQKEAVVSQGES HLNVSWRSSE NHPNLTCTAS NPVSRSSHQFLSENICSGPERNTK
预测分子量	39 kDa
蛋白标签	His tag N-Terminus
缓冲液	PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
稳定性 & 储存条件	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
复溶	Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

参考文献

以下是关于LY9重组蛋白的虚构参考文献示例，基于合理推测的研究方向整理：

---

1. **标题**：*Structural Characterization of Recombinant LY9 Extracellular Domain and Its Interaction with SLAMF6*

**作者**：Smith, J.R. et al.

**期刊**：*Journal of Biological Chemistry* (2018)

**摘要**：本研究通过X射线晶体学解析了LY9重组蛋白胞外域的三维结构，揭示了其独特的Ig样结构域排列。实验证实LY9与SLAMF6蛋白通过特定表位结合，为理解其在T/B细胞免疫突触中的作用提供了结构基础。

2. **标题**：*LY9 Recombinant Protein Modulates B Cell Activation via Synergistic Signaling with CD19*

**作者**：Zhang, L. et al.

**期刊**：*Immunity* (2020)

**摘要**：利用LY9重组蛋白和基因敲除小鼠模型，研究发现LY9与CD19共定位于B细胞表面，协同增强PI3K-Akt信号通路，促进B细胞增殖及抗体分泌，提示其在适应性免疫中的调控作用。

3. **标题**：*Targeting LY9 with Recombinant Fusion Protein Attenuates Autoimmunity in Lupus-Prone Mice*

**作者**：Patel, S. et al.

**期刊**：*Nature Communications* (2021)

**摘要**：通过构建LY9-Fc重组融合蛋白，研究团队证明其可阻断LY9与配体的病理相互作用，显著降低MRL/lpr小鼠模型的肾脏炎症和自身抗体水平，为治疗系统性红斑狼疮提供了新策略。

4. **标题**：*LY9 Recombinant Protein as a Biomarker for Lymphoma Progression*

**作者**：Kim, Y. et al.

**期刊**：*Blood* (2022)

**摘要**：分析弥漫大B细胞淋巴瘤患者样本发现，LY9重组蛋白的高表达与肿瘤侵袭性正相关。体外实验显示LY9通过ERK通路促进细胞迁移，提示其作为预后标志物和治疗靶点的潜力。

---

注：上述文献为虚构示例，实际研究中请通过学术数据库(如PubMed、Web of Science)检索真实文献。

背景信息

**Background of LY9 Recombinant Protein**

LY9 (also known as SLAMF3 or CD229) is a member of the signaling lymphocytic activation molecule (SLAM) family, a group of cell-surface receptors involved in modulating immune responses. These proteins play critical roles in immune cell communication, particularly in T-cell and B-cell activation, adhesion, and homeostasis. LY9 is expressed predominantly on lymphocytes, including T cells, B cells, and dendritic cells, and interacts with specific ligands to regulate both activating and inhibitory signals in immune pathways.

Structurally, LY9 features an extracellular region with two immunoglobulin-like domains (V and C2 types), a transmembrane domain, and a cytoplasmic tail containing immunoreceptor tyrosine-based switch motifs (ITSMs). These motifs recruit adaptor proteins like SAP (SLAM-associated protein), facilitating downstream signaling. LY9’s dual role in immune regulation—enhancing lymphocyte activation while also contributing to immune tolerance—has made it a focus in studies of autoimmune diseases, immunodeficiency disorders, and cancer immunotherapy.

Recombinant LY9 protein is engineered *in vitro* using expression systems (e.g., mammalian cells or *E. coli*) to produce soluble, functional forms of the protein for research and therapeutic development. It retains the ligand-binding capability of native LY9. enabling studies on receptor-ligand interactions, immune synapse formation, and signaling mechanisms. In drug discovery, recombinant LY9 serves as a tool for screening antibodies or small molecules targeting LY9-mediated pathways. Recent studies explore its potential as a biomarker or therapeutic target, particularly in contexts like lupus or lymphoproliferative diseases.

Efforts to optimize LY9 recombinant protein focus on purity, stability, and post-translational modifications to mimic native functionality, ensuring relevance in both basic research and clinical applications.